Grant: CIHR Fellowship
Direct Payment
$150,000.00
Deconvoluting the role of diet and obesity in prostate cancer susceptibility through epigenomics
EF 2012-13
Résumé
Prostate cancer is the most frequently diagnosed cancer in North American men and the second leading cause of cancer-related death. Still, androgen deprivation therapy has remained the sole treatment for advance disease since its description in 1941, although it ultimately leads to an incurable castration-resistant disease. Therefore, the field urgently needs an innovative approach to prevent and treat prostate cancer before it reaches a more advanced stage.
Diet and obesity are among the risk factors associated with prostate cancer. Strikingly, the disparity in prostate cancer incidence between the Eastern and the Western part of the World clearly advocate for the crucial role of environmental factors in the etiology of the disease. Prostate cancer is characterized by complex genomic alterations that are highly heterogeneous and greatly varies from a patient to another and even within the same tumor. Such disparities could be partly explained by an underlying genomic instability. In fact, prostate cancer has been described as an epigenome catastrophe, suggesting that epigenetic changes (i.e. modifications to the DNA) are pivotal events in prostate cancer initiation. Diet can induce various epigenetic modifications that result as global alterations in DNA packaging. Such stable and heritable changes regulate the access of the transcriptional machinery to their target genes and completely alter cellular behavior.
Our working hypothesis is that specific diets and chronic obesity induce profound epigenetic modifications leading to increased genomic instability, which contributes to prostate cancer development. Tackling this hypothesis using various animal models, human tissues and cutting edge genome-wide technologies represent a novel and promising approach in prostate cancer research. We trust that understanding those epigenetic modifications will allow us to point to non-pharmacological means as well as targeted therapy to prevent or treat prostate cancer.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
280012
Name
Labbé David
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Deconvoluting the role of diet and obesity in prostate cancer susceptibility through epigenomics
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Bioinformatics; Chromatin Immunoprecipitation-Sequencing; Diet; Dnase I Hypersensitive Sites; Epigenomics; Human Tissues; Mouse Models; Obesity; Prostate Cancer; Transcription Factors
Abstract
Prostate cancer is the most frequently diagnosed cancer in North American men and the second leading cause of cancer-related death. Still, androgen deprivation therapy has remained the sole treatment for advance disease since its description in 1941, although it ultimately leads to an incurable castration-resistant disease. Therefore, the field urgently needs an innovative approach to prevent and treat prostate cancer before it reaches a more advanced stage.
Diet and obesity are among the risk factors associated with prostate cancer. Strikingly, the disparity in prostate cancer incidence between the Eastern and the Western part of the World clearly advocate for the crucial role of environmental factors in the etiology of the disease. Prostate cancer is characterized by complex genomic alterations that are highly heterogeneous and greatly varies from a patient to another and even within the same tumor. Such disparities could be partly explained by an underlying genomic instability. In fact, prostate cancer has been described as an epigenome catastrophe, suggesting that epigenetic changes (i.e. modifications to the DNA) are pivotal events in prostate cancer initiation. Diet can induce various epigenetic modifications that result as global alterations in DNA packaging. Such stable and heritable changes regulate the access of the transcriptional machinery to their target genes and completely alter cellular behavior.
Our working hypothesis is that specific diets and chronic obesity induce profound epigenetic modifications leading to increased genomic instability, which contributes to prostate cancer development. Tackling this hypothesis using various animal models, human tissues and cutting edge genome-wide technologies represent a novel and promising approach in prostate cancer research. We trust that understanding those epigenetic modifications will allow us to point to non-pharmacological means as well as targeted therapy to prevent or treat prostate cancer.
Competitiondate
201302
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Labbé, David
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~